Right now almost every company in the pharmaceutical sector is caught in a bear market, with exception of Johnson & Johnson. While the drug index is down 9 percent for the year, Johnson & Johnson has actually managed to rally more than 4 percent.
What made the success more stunning to Cramer was that for years, Johnson & Johnson had been one of the worst performers in the industry. The rebound might seem sudden, but it has actually been in the works for a long time.
"The truth is that Johnson & Johnson is finally benefitting from a turnaround that was many years in the making, a comeback that has been spearheaded by CEO Alex Gorsky. Yes, the difference here is all about leadership," the "Mad Money" host said.